← All trials
NCT04632862
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 11, 2020
- Primary completion
- Aug 31, 2021
- Completion date
- Nov 30, 2021
- First posted
- Nov 17, 2020
- Last posted
- Nov 17, 2020
- Enrollment
- 140
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Daewoong Pharmaceutical Co. LTD.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.